TNFSF11 and Fabry disease: A clinical trial performed by our group using the anti-RANKL drug denosumab was shown successfully halt bone resorption in FD, and to prevent proliferation of altered BMSCs, leading to decreased cellularity, and normalized differentiation of affected BMSCs.